Sigilon Therapeutics Inc. (SGTX): Price and Financial Metrics

Sigilon Therapeutics Inc. (SGTX): $22.47

0.59 (-2.56%)

POWR Rating

Component Grades








Add SGTX to Watchlist
Sign Up

Industry: Biotech




#164 of 458

in industry

SGTX Price/Volume Stats

Current price $22.47 52-week high $28.00
Prev. close $23.06 52-week low $3.77
Day low $22.09 Volume 83,600
Day high $23.10 Avg. volume 62,902
50-day MA $14.79 Dividend yield N/A
200-day MA $9.81 Market Cap 56.49M

SGTX Stock Price Chart Interactive Chart >

SGTX Stock Summary

  • SIGILON THERAPEUTICS INC's stock had its IPO on December 4, 2020, making it an older stock than just 11.87% of US equities in our set.
  • Revenue growth over the past 12 months for SIGILON THERAPEUTICS INC comes in at 49.27%, a number that bests 87.39% of the US stocks we're tracking.
  • In terms of volatility of its share price, SGTX is more volatile than 99.84% of stocks we're observing.
  • Stocks that are quantitatively similar to SGTX, based on their financial statements, market capitalization, and price volatility, are BPMC, SRZN, BCDA, RXRX, and SLDP.
  • SGTX's SEC filings can be seen here. And to visit SIGILON THERAPEUTICS INC's official web site, go to

SGTX Valuation Summary

  • SGTX's price/sales ratio is 3.6; this is 71.43% higher than that of the median Healthcare stock.
  • SGTX's EV/EBIT ratio has moved up 17.2 over the prior 32 months.

Below are key valuation metrics over time for SGTX.

Stock Date P/S P/B P/E EV/EBIT
SGTX 2023-07-26 3.6 1.6 -1.4 -1.0
SGTX 2023-07-25 3.6 1.6 -1.4 -1.0
SGTX 2023-07-24 3.6 1.6 -1.4 -1.0
SGTX 2023-07-21 3.6 1.6 -1.4 -1.0
SGTX 2023-07-20 3.7 1.6 -1.4 -1.1
SGTX 2023-07-19 3.7 1.6 -1.5 -1.1

SGTX Price Target

For more insight on analysts targets of SGTX, see our SGTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.75 Average Broker Recommendation 1.38 (Strong Buy)

Sigilon Therapeutics Inc. (SGTX) Company Bio

Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

SGTX Latest News Stream

Event/Time News Detail
Loading, please wait...

SGTX Latest Social Stream

Loading social stream, please wait...

View Full SGTX Social Stream

Latest SGTX News From Around the Web

Below are the latest news stories about SIGILON THERAPEUTICS INC that investors may wish to consider to help them evaluate SGTX as an investment opportunity.

Biotech Stock Roundup: BMRN's Gene Therapy Gets Approval, SGTX Up on Buyout by LLY

Regulatory and acquisition updates from BioMarin (BMRN) and Sigilon (SGTX) are in focus in the biotech sector.

Yahoo | July 6, 2023

Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly

Eli Lilly (LLY) is set to acquire Sigilon (SGTX) for $14.92 per share, in cash, along with a contingent value right of $111.64 per share.

Yahoo | June 30, 2023

Why Is Cormedix (CRMD) Stock Down 23% Today?

Cormedix (CRMD) stock is falling hard on Thursday with heavy trading after the company priced a public offering of its shares.

William White on InvestorPlace | June 29, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

We're starting Thursday with a detailed look at all of the biggest pre-market stock movers worth keeping an eye on today!

William White on InvestorPlace | June 29, 2023

Why Is BioXcel Therapeutics (BTAI) Stock Down 57% Today?

BioXcel Therapeutics (BTAI) stock is taking a beating on Thursday after the company released its latest clinical trial data.

William White on InvestorPlace | June 29, 2023

Read More 'SGTX' Stories Here

SGTX Price Returns

1-mo N/A
3-mo 4.27%
6-mo 138.84%
1-year 238.25%
3-year N/A
5-year N/A
YTD 393.85%
2022 -87.32%
2021 -94.25%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!